Access the full text.
Sign up today, get DeepDyve free for 14 days.
O. Lyytikäinen, P. Ruutu, J. Ollgren, J. Nuorti, M. Norton, Å. Örtqvist (2008)
Invasive pneumococcal infections among persons with and without underlying medical conditions: Implications for prevention strategiesBMC Infectious Diseases, 8
A. Mitchell, T. Mitchell (2010)
Streptococcus pneumoniae: virulence factors and variation.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 16 5
M. Corcoran, I. Vickers, J. Mereckiene, S. Murchan, S. Cotter, M. Fitzgerald, M. McElligott, M. Cafferkey, D. O'flanagan, R. Cunney, Hilary Humphreys (2017)
The epidemiology of invasive pneumococcal disease in older adults in the post-PCV era. Has there been a herd effect?Epidemiology and Infection, 145
Alan Johnson, P. Waight, N. Andrews, R. Pebody, R. George, E. Miller (2007)
Morbidity and mortality of pneumococcal meningitis and serotypes of causative strains prior to introduction of the 7-valent conjugant pneumococcal vaccine in England.The Journal of infection, 55 5
C. Feldman, R. Anderson (2014)
Recent advances in our understanding of Streptococcus pneumoniae infectionF1000Prime Reports, 6
Regine Cherazard, M. Epstein, Thien-Ly Doan, Tanzila Salim, Sheena Bharti, Miriam Smith (2017)
Antimicrobial Resistant Streptococcus pneumoniae: Prevalence, Mechanisms, and Clinical ImplicationsAmerican Journal of Therapeutics, 24
R. Hardie, L. King, R. Fraser, M. Reid (2009)
Prevalence of pneumococcal polysaccharide vaccine administration and incidence of invasive pneumococcal disease in children in Jamaica aged over 4 years with sickle cell disease diagnosed by newborn screeningAnnals of Tropical Paediatrics, 29
(2015)
ASM Press
R. Reinert (2009)
The antimicrobial resistance profile of Streptococcus pneumoniae.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 15 Suppl 3
Åke Örtqvist1, Jonas Hedlund1, Mats Kalin1 (2005)
Streptococcus pneumoniae: Epidemiology, Risk Factors, and Clinical FeaturesSeminars in Respiratory and Critical Care Medicine, 26
U. Allen, Sonia Thomas, J. Carapetis, S. Henry, S. Wasfy, M. Lovgren, S. Richardson, D. Low (2003)
Serotypes of respiratory tract isolates of Streptococcus pneumoniae from Jamaican children.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 7 1
H. Iannella, C. Luna (2016)
Community-Acquired Pneumonia in Latin AmericaSeminars in Respiratory and Critical Care Medicine, 37
B. Charalambous, S. Batt, A. Peek, H. Mwerinde, Noel Sam, Stephen Gillespie (2003)
Quantitative Validation of Media for Transportation and Storage of Streptococcus pneumoniaeJournal of Clinical Microbiology, 41
Joseph Lynch1, George Zhanel2 (2009)
Streptococcus pneumoniae: Epidemiology, Risk Factors, and Strategies for PreventionSemin Respir Crit Care Med, 30
D. McGregor, M. Barton, S. Thomas, Celia Christie (2004)
Invasive pneumococcal disease in Jamaican childrenAnnals of Tropical Paediatrics, 24
W. Wong, G. Overturf, D. Powars (1992)
Infection caused by Streptococcus pneumoniae in children with sickle cell disease: epidemiology, immunologic mechanisms, prophylaxis, and vaccination.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 14 5
BACKGROUND:Pneumococcal infections are a leading global cause of morbidity and mortality, complicated by the increasing antimicrobial resistance of pneumococcal isolates.OBJECTIVE:To evaluate morbidity and mortality associated with both invasive pneumococcal disease (IPD) and non-IPD in Jamaica in both the paediatric and adult population. Pneumococcal isolates (n= 94) were collected over a 2-year period (2008–2009).METHODS:Risk factors for poor clinical outcomes: death, complicated disease and length of hospitalization (LOH) were evaluated and antimicrobial resistance patterns were determined by Kirby-Bauer disc diffusion.RESULTS:The case fatality rate was 6.8%. Independent mortality risk factors included complicated disease [OR 30.9 (3.4–276.6)] and diabetes mellitus [OR 8.3 (1.4–48.8)]. Independent risk factors for the development of complicated disease included sickle cell disease [OR 36.5 (4.2–320.3)] and sepsis [OR 3.5 (1.2–10.4)]. The LOH was increased most in patients with invasive disease (4.6-fold) and resistance to ceftriaxone (4.3-fold). Penicillin (16.0%) and erythromycin (14.9%) resistance was most prevalent, while ceftriaxone (4.3%) resistance was least prevalent.CONCLUSIONS:The high burden of IPD in at-risk groups in our population and the associated increase in morbidity and mortality underlie the need for improved preventive and therapeutic management strategies in these patients.
Human Antibodies – IOS Press
Published: Jan 1, 2019
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.